Five Prime Therapeutics

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutics to improve the lives of patients with serious diseases. The Company currently has three product candidates in clinical development covering multiple potential indications. Cabiralizumab (FPA008) is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis and in multiple cancers in combination with Bristol-Myers Squibb Company’s PD-1 immune checkpoint inhibitor, Opdivo (nivolumab). FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that we are initially developing to treat patients with gastric (stomach) cancer and is in a Phase 1 clinical trial. FP-1039 is a fusion protein that “traps” and neutralizes cancer-promoting fibroblast growth factors, or FGFs, involved in cancer cell proliferation and new blood vessel formation that is in Phase 1b clinical development to treat patients with malignant pleural mesothelioma.

Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
2001
Size (employees)
195 (est)
Five Prime Therapeutics was founded in 2001 and is headquartered in South San Francisco, US

Key People/Management at Five Prime Therapeutics

Aron Knickerbocker

Aron Knickerbocker

Chief Operating Officer
Marc Belsky

Marc Belsky

Senior Vice President and Chief Financial Officer

Five Prime Therapeutics Office Locations

Five Prime Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
2 Corporate Dr

Five Prime Therapeutics Financials and Metrics

Five Prime Therapeutics Financials

USD

Net income (Q3, 2017)

(43.3 b)

EBIT (Q3, 2017)

(44.1 b)

Market capitalization (11-Dec-2017)

661.6 m
Five Prime Therapeutics's current market capitalization is $661.6 m.
USDFY, 2013FY, 2016

R&D expense

94.1 b

General and administrative expense

35.8 b

Operating expense total

129.9 b

EBIT

(29.4 m)(99.2 b)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

R&D expense

13.3 m24.7 m18.3 b22.2 b23.9 b33.8 b41.7 m

General and administrative expense

4.6 m5.2 m8.6 b8.1 b9.1 b10.5 b9.4 m

Operating expense total

17.9 m29.9 m26.9 b30.3 b33 b44.2 b51.1 m52.4 b

EBIT

(11.6 m)(24.1 m)(20.4 b)(21.1 b)(26.4 b)(34.1 b)(43.3 m)(44.1 b)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

8.2 m15.3 m150 m7.7 m

Current Assets

77.7 m151.3 m528.3 m440.1 m

PP&E

3.7 m3.8 m4.5 m6.2 m

Total Assets

81.8 m155.6 m548.3 m448.3 m
USDQ3, 2017

Accounts Payable

2.9 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (28.9 m)(37.4 m)249.6 m(65.7 m)

    Depreciation and Amortization

    1.7 m1.6 m1.7 m1.7 m

    Accounts Payable

    (209 k)701 k798 k(1.6 m)

    Cash From Operating Activities

    (25.3 m)15.3 m289.1 m(79.8 m)
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    (11.5 m)(24 m)(13 b)(13.1 b)(19.4 b)(33.4 b)(43.3 b)

    Accounts Payable

    3.8 m347 k767 k672 k904 k1.4 m1.6 m1 m654 k528 k807 k1.3 m2.9 m
      Show all financial metrics

      Five Prime Therapeutics Market Value History

      Five Prime Therapeutics's Web-traffic and Trends

      Five Prime Therapeutics Online and Social Media Presence

      Five Prime Therapeutics Company Life and Culture

      You may also be interested in